Trial Profile
Phase II trial of the combination of SPM-011 and BNCT System for recurrent malignant glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Borofalan (10B) (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stella Pharma; Sumitomo Heavy Industries
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 28 Apr 2016 New trial record